Harrow Revives TRIESENCE®: A Breakthrough for Eyecare
Harrow Bridges the Gap in Eyecare with TRIESENCE® Relaunch
NASHVILLE, Tenn. — Harrow (NASDAQ: HROW), a prominent player in the North American eyecare pharmaceutical sector, has officially relaunched TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid holds the approval of the U.S. Food and Drug Administration (FDA) and is utilized for enhancing visibility during vitrectomy procedures as well as treating ocular inflammation that might not respond to standard topical treatments.
Significance of TRIESENCE® in Eyecare
The reintroduction of TRIESENCE is crucial according to Mark L. Baum, Chairman and CEO of Harrow. Baum expressed, “We are thrilled to reintroduce TRIESENCE to the U.S. market, allowing ophthalmologists to access this FDA-approved product that has positively impacted millions of patients. This relaunch involved a significant rebuilding of the supply chain and extensive collaboration with technical experts globally, showcasing the team's dedication and commitment.”
Expert Opinions on TRIESENCE®
Dr. Rishi Singh, an esteemed ophthalmologist from Cleveland Clinic, highlighted the importance of having an FDA-approved, preservative-free option available for both office procedures and surgical interventions. He noted that TRIESENCE provides enhanced visibility during vitrectomy due to its unique characteristics, combating the challenges experienced during its absence.
Moreover, Dr. John W. Kitchens, a retina surgeon from Kentucky, shared, “We are incredibly thankful to Harrow for their vigorous efforts to bring TRIESENCE back. Its anti-inflammatory capabilities are indispensable for managing severe ocular conditions that need specialized care. The return of this vital resource ensures we can provide the best treatment options for our patients.”
Ordering and Availability of TRIESENCE®
Healthcare professionals interested in acquiring TRIESENCE can do so through major pharmaceutical specialty distributors like Besse Medical/Cencora, McKesson Medical-Surgical, and Cardinal Health. The initial supply will be available under NDC 00078-0897-78 and NDC 82667-800-01, ensuring a streamlined process for eyecare practitioners.
About Harrow
Harrow, Inc. (NASDAQ: HROW) is dedicated to developing innovative ophthalmic pharmaceuticals aimed at enhancing patient care in North America. Their efforts focus on making affordable, accessible options available to millions, supporting eyecare professionals as they strive to preserve vision. To learn more about their offerings, please visit harrow.com.
FAQs
What is TRIESENCE® used for?
TRIESENCE is indicated for use in ocular inflammation and providing visibility during vitrectomy procedures, aiding in better surgical outcomes.
Why is the relaunch of TRIESENCE® important?
The relaunch of TRIESENCE fills a crucial gap in the market for preservative-free corticosteroids, enhancing treatment options for patients and professionals.
How can healthcare providers order TRIESENCE®?
Healthcare providers may order TRIESENCE directly through specialty pharmaceutical distributors such as McKesson and Cardinal Health.
Who manufactures TRIESENCE®?
TRIESENCE is manufactured by Harrow, a leading company in the eyecare pharmaceutical industry focused on innovative solutions.
What are the benefits of using TRIESENCE®?
Its benefits include effective anti-inflammatory properties aiding in ocular conditions and improved visibility during surgeries, thus enhancing patient safety and treatment effectiveness.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.